Tuesday 29th March Plenary sessions are shared across all conferences


Cancer & Immunotherapy, Tuesday 29 March 2016

Dr Gregory A. Poland

Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
Dr Gregory A. Poland

Vaccinomics and vaccinology 3.0 – The way forward

  • Vaccinomics, adversomics and the immune response network theory: Individualized vaccinology in the 21st century
  • New understandings of how vaccines stimulate immune responses, new biomarkers for vaccine response, and facilitate the understanding of what genetic and other factors might be responsible for rare side effects due to vaccines
  • Integrating increasingly complex high throughput data into descriptive and predictive equations for immune responses to vaccines
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
Dr. Leonard Friedland

Vaccine adjuvant science: Understanding modern vaccines

  • Novel adjuvant systems under investigation by GSK and safety considerations
  • Learning and challenges in combining adjuvants including pre-clinical and clinical experience
  • Experience and considerations for use in special populations
  • Potential application of adjuvants to future vaccines (experience with adjuvanted investigational zoster vaccine), and adjuvant communication to healthcare providers and patients
Dr. Leonard Friedland, VP, Scientific Affairs and Public Health Vaccines, North America, GSK
Dr Peter Hotez

Developing a new generation of neglected disease vaccines

  • New human hookworm and schistosomiasis vaccines now in clinical trials and earlier stage vaccines for Chagas disease, leishmaniasis
  • Building vaccine development capacity in critical areas threatened by poverty and conflict, including ISIS held territories with the White House and State Department US Science Envoy
Dr Peter Hotez, President of the Sabin Vaccine Institute and Dean of National School of Tropical Medicine, Baylor College of Medicine

Networking Coffee Break



Vaccinating the anti-vaxxers
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences

The need for a vaccine development fund 
Prof Stanley A. Plotkin, Emeritus Professor, University of Pennsylvania & Executive Advisor, Sanofi Pasteur
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic

How can the pharma/CRO industry better collaborate with the site networks?
Lynlee Burton, Director of Project Delivery – Vaccines, PRA Health Sciences

Practical issues around inclusion/exclusion criteria and protocol design with their impact on time-lines, data collection, and quality of subjects
Prof William B. Smith, Founder, President, and Principal Investigator NOCCR/VRG

Overcoming hurdles in technology transfer & IP
Dr Mukul Ranjan, Senior Advisor for Innovation and Technology Transfer, National Institute of Allergy and Infectious Diseases

Considerations for global clinical vaccine studies
Dr Cynthia Dukes, VP Global Project Management, Vaccines, Infectious Diseases, Women’s Health and Primary Care, ICON Clinical Research

New approaches to accessing patient populations: Adults in G8 markets, middle income countries and helping Gavi-funded governments reach the fifth child
Tara Azimi, Expert Associate Principal, McKinsey & Company
Aliza Apple, Engagement Manager, McKinsey & Company

Designing effective processes to enable scalability of vaccine products
Dr Joseph G. Joyce, Director, Vaccine Process Development, Merck Research Laboratories

A Transition to Targeted or “Smart” Vaccines: How Understanding Commensal Colonization Can Lead to Selective Vaccination
Dr Blaine Pfeifer, Associate Professor, Chemical and Biological Engineering Department, State University of New York at Buffalo

The issue of virally-induced cancers: Barriers to awareness
Dr Lopa Mishra, Director, Center for Translational Research Department of Surgery and GWU Cancer Center, George Washington University

From surrogate markers to predictive biomarkers of vaccine efficacy: How realistic is to enhance the blood markers beyond serum antibody?
Dr Ali Harandi, Associate Professor, Lab head, University of Gothenburg

Challenges and Opportunities in Conducting Clinical Trials in West Africa

Dr David Hoover, Senior Medicial Advisor, Clinical RM
Dr Kevin J. Gilligan, Senior Scientific Advisor, Clinical RM

Zika virus: Challenges for medical countermeasure development
Dr Robert Malone, CEO and Consultant, RW Malone MD, LLC
Pre-clinical biomarkers of safety and efficacy in vaccine design and development
Dr Michael Vajdy, Co-Founder, President and Chief Scientific Officer, Epito Genesis Inc
Adjuvants and technology advancements driving vaccine R&D
Dr Michel De Wilde, Former Senior Vice President R&D of Sanofi Pasteur & Owner, MDW Consultant LLC


Networking Lunch

Dr Heather Sings

An interactive point-count point discussion: Polysaccharide vs conjugate pneumococcal vaccine

  • Policy recommendations for pneumococcal vaccination around the world
  • Amount of disease caused by vaccine serotypes
  • Indirect protection in adults from pediatric use of PCV13
  • Vaccine effectiveness and other immunologic considerations
  • Carriage, duration of protection and cost effectiveness
Dr Heather Sings, Senior Director and Medical Lead, Pneumococcal Vaccines, Pfizer
Dr Melvin Kohn, Medical Director for Adult Vaccines, Merck Vaccines
Dr Laura York

An interactive joint presentation on the FDA approved meningococcal B vaccines

  • The science behind different approaches
  • Discussing the different approaches in getting FDA approval
  • Predictions of effectiveness in additional strains
Dr Laura York, VP, Global Meningococcal Vaccines, Medical Development and Scientific/Clinical Affairs, Pfizer
Dr Rino Rappuoli, Chief Scientist, GSK Vaccines
Dr Wellington Sun

Regulating vaccines at the FDA: Development and licensure of Ebola vaccines

  • What have we learnt from the Ebola crisis?
  • How quickly can we work together to help speed up the process of licensure?
  • How will we respond to the next threat?
Dr Wellington Sun, Director Division of Vaccines and Related Products Applications CBER, U.S. Food and Drug Administration

Networking coffee break

James Mansi

A century of vaccine development & innovation: Ensuring novel influenza vaccines are available to meet the needs of diverse patients groups

  • Vaccines developed for the young, the old, and everyone in between
  • Moving from traditional needle and syringe to innovative needle-free delivery systems
  • Transition from traditional trivalent flu vaccines to quadrivalent, cell culture based, and adjuvanted vaccines
James Mansi, Global Head, Medical Affairs, Novartis Influenza Vaccines
Dr Gary Nabel

What is the vision for a HIV vaccine? Has it changed in the last decade?

  • Update on the clinical trials and their progress
  • Has the sense of urgency for a HIV vaccine lost its momentum with effective preventative methods that can stop/limit transmission
  • Could HIV eliminate itself eventually?
  • The vision for a vaccine to replace all preventative methods 
Dr Gary Nabel, Senior Vice President and Chief Scientific Officer, Sanofi Inc
Rahul Singhvi

The future sustainability of vaccines - What pressure does the industry suffer from that could prevent access to vaccine?

-How will the industry look in 10 years? Understanding the industry dynamics and factors that will give you a competive advantage
-Addressing the obstacles poised in market access and manufacturing
-How to treat the vaccine industry differently to the pharmaceutical industry as a whole, using value based pricing as an example
Rahul Singhvi, Chief Operating Officer, Takeda Vaccines, Inc.
Dr Gregory A. Poland

Chair’s closing remarks and close of congress day 1

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation

Pre-Awards Networking Drinks Reception


Gala Dinner & ViE Awards Ceremony

last published: 24/Mar/16 11:25



Cancer & Immunotherapy, Wednesday 30 March 2016

Dr James Merson
Cancer & Immunotherapy

Chair’s opening remarks

Dr James Merson, CSO Vaccine Immunotherapeutics, Pfizer Inc
Prof David Weiner
Cancer & Immunotherapy

Synthetic cancer DNA vaccines: Targeting tumors that hide through multiple arms of the immune system

  • Applications to important cancer targets including  lung, breast, pancreatic, head and neck cancers
  • Breaking the tolerance of the immune system to target the tumor synthetic approaches to anti-tumor immunity humoral as well as cellular immunity
Prof David Weiner, WW Smith Endowed Chair in Cancer Research, Director Wistar Vaccine Center, EVP of The Wistar Institute, Professor Emeritus, University of Pennsylvania School of Medicine
Dr Niranjan Sardesai
Cancer & Immunotherapy

Translating DNA vaccines and immunotherapies into advanced clinical studies

  • Optimizing antigens and efficient DNA delivery to elicit potent immune responses and drive clinical efficacy
  • Cancer targets and combination immunotherapies
  • Scaling from pilot-scale to commercial production
Dr Niranjan Sardesai, COO, Inovio
Dr Duane Mitchell
Cancer & Immunotherapy

LAMP-modified RNA-loaded dendritic cell vaccines for glioblastoma

  • Developing a broadly applicable immunotherapy platform to induce specific T cells, including memory populations, through LAMP, which enhances/directs antigen presentation through MHC - II
  • Applied in Ph I/II clinical trials in oncology for certain indications in patients diagnosed with GBM, AML and melanoma
  • Expanding on other oncology initiatives active at ITI and through collaborators
Dr Duane Mitchell, Director, University Of Florida

Networking coffee break

Dr Peter Brown
Cancer & Immunotherapy

SCIB1 ImmunoBody stimulates a potent T cell response that eradicates tumours and prevents recurrence

  • SCIB1 ImmunoBody DNA vaccine, delivered using electroporation (TriGrid, Ichor Medical Sysytems), stimulates potent T cell responses and encouraging recurrence-free and overall survival times in melanoma patients
  • Patients may benefit from de novo high avidity T cell responses prior to checkpoint blockade
  • SCIB1 offers potential for use in combination with checkpoint blockade for advanced disease and as an adjuvant therapy for earlier stage disease
Dr Peter Brown, Clinical and Scientific Consultant, Immunotherapeutics, Scancell Holdings plc
Lars Staal Wegner
Cancer & Immunotherapy

Optimizing poxvirus-based immunotherapeutics for tumor-specific immune response

  • Overview of Bavarian Nordic’s pox-based immunotherapeutic and vaccine platforms
  • Tumor-specific immunotherapeutics currently in development include PSA-targeted PROSTVAC; CV-301 (targeting CEA and MUC-1); as well as MVA-BN-HER2 and MVA-BN-Brachyury
  • Combining poxvirus-based active immunotherapy and immune checkpoint blockade can result in synergistic anti-tumor efficacy
Lars Staal Wegner, Vice President of Commercial Affairs, Bavarian Nordic A/S
Dr David E. Anderson
Cancer & Immunotherapy

More Foreign than Neo: Harnessing the power of viral CMV antigens to target glioblastoma

  • Recent data suggests novel new antigens may play a key role in re-awakening anti-tumor immunity
  • CMV antigens are expressed in over 90% of glioblastoma tumors
  • As a highly immunogenic, foreign viral antigen, VBI presents a novel anti-GBM vaccine approach through CMV targeting 
Dr David E. Anderson, Senior Vice President, Research, Vbi Vaccines
Dr Richard Lesniewski
Cancer & Immunotherapy

Clinical assessment of DNA vaccines across three distinct stages of malignant prostate cancer

  • Ongoing clinical trials of a PAP-targeting DNA vaccine (MVI-816):
  • Phase 2 as monotherapy for men with biochemically recurrent prostate cancer
  • Phase 1/2, in combination with Keytruda®, for men with metastatic, castrate-resistant prostate cancer
  • Androgen receptor (AR) as a target for immunological therapy for prostate and other cancers
  • Ongoing Phase 1 clinical trial with an AR-targeting DNA vaccine (MVI-118) in men with metastatic prostate cancer who are initiating androgen deprivation therapy 
Dr Richard Lesniewski, President and CEO, Madison Vaccines Inc.
Dr Chan Whiting
Cancer & Immunotherapy

Cancer Immunotherapy using Live-Attenuated Listeria monocytogenes and Cyclic Dinucleotides

  • Breakthrough therapy designation from FDA for innovative pancreatic cancer combination immunotherapy
  • Combinations of LADD with GVAX, chemotherapy and checkpoint inhibitors
  • Plans to include trials combining with radiation, hormonal therapies, antibodies and other therapeutic agents
  • Design, development and rationale for ADU-S100, a novel synthetic STING-specific cyclic dinucleotide for activation of tumor-initiated T cell priming
Dr Chan Whiting, Director, Immune Monitoring and Biomarker Development, Aduro Biotech

Networking Lunch

Dr Robert Petit
Cancer & Immunotherapy

Realizing the promise of neoantigens: Using live attenuated bacteria to generate personalized cancer immunotherapies

  • Stimulating the innate and adaptive arms of the immune system and the potential reduction in tumor defense mechanisms
  • PhIII data of cervical cancer patients and applications to other cancers
  • Potential for combination of Lm vectors with checkpoint inhibitors and co-stimulatory agonists
Dr Robert Petit, Chief Scientific Officer, Executive Vice President,, Advaxis
Ms Linda Powers
Cancer & Immunotherapy

DCVax®: Novel personalized immune therapies for solid tumors

  • NW Bio’s DCVax platform technology
  • DCVax is a personalized, dendritic cell-based active immunotherapy for solid tumor cancers
  • Unlike conventional cancer treatments, which typically direct one active agent against one cancer target, DCVax mobilizes many active agents of the immune system to hit many targets on the cancer
Ms Linda Powers, Chief Executive Officer, Northwest Biotherapeutics Inc
Dr Jerome Galon
Cancer & Immunotherapy

Using Immunescore as a new approach for the classification of colon cancer

  • Exciting new data that validates immunoscore’s potential and applications
  • How to understand the host immune response against cancer during tumor evolution? 
  • The future of combinational cancer therapies and cancer vaccines to develop personalized
  • medicine
Dr Jerome Galon, Director, Centre De Recherche Des Cordeliers

Networking coffee break

Dr Roy Baynes
Cancer & Immunotherapy

Optimizing the therapeutic benefit of PD-1 blockade and broadening the potential of immunotherapy

  • Summarize PD-1 antibody activity an extremely broad based antineoplastic therapy
  • Outline the rationale for next generation combination immunotherapies
  • Safety and efficacy of combining other anticancer treatments and immunomodulators with KEYTRUDA® such as Chemotherapy, radiation therapy, targeted therapies, other check point inhibitors, costimulatory molecules, oncolytic viruses and tumor vaccines
Dr Roy Baynes, Senior Vice President of Global Clinical Development, Merck Research Laboratories
Dr James Merson
Cancer & Immunotherapy

Vaccine based immunotherapy regimen (VBIR) for the treatment of prostate cancer

  • Application of lessons learned for the development of cancer immunotherapy combinations
  • Attributes of a heterologous vaccine that induces poyvalent tumor antigen immune responses
  • Use of immunomodulators to expand tumor antigen immune responses and maintain anti-tumor activity in the immunosuppressive tumor micro-environment
Dr James Merson, CSO Vaccine Immunotherapeutics, Pfizer Inc
Panel discussion
Cancer & Immunotherapy

Panel: The future combination cancer immunotherapies with vaccines, checkpoint inhibitors and oncolytic viruses

  • Cancer therapies are all heading to combinational approaches but how do we fine tune what should be combined and in what order?
  • How will combinational approaches reduce side effects and replace conventional treatments including chemotherapy?
Dr Jessica Baker Flechtner, Chief Scientific Officer, Genocea Biosciences, Inc.
Dr Jay A. Berzofsky, Branch Chief, Vaccine Branch, National Cancer Institute - NIH
Dr Lelia Delamarre, Group Leader, Cancer Immunotherapy Department, Genetech
Dr Roy Baynes, Senior Vice President of Global Clinical Development, Merck Research Laboratories
Dr Rakesh Dixit, Vice President R and D, Global Head, Biologics Safety Assessment, MedImmune Inc
Dr James Merson
Cancer & Immunotherapy

Chair’s closing remarks and close of congress day 2

Dr James Merson, CSO Vaccine Immunotherapeutics, Pfizer Inc
last published: 24/Mar/16 11:26



Cancer & Immunotherapy, Thursday 31 March 2016

Dr James Merson
Cancer & Immunotherapy

Chair opening remarks

Dr James Merson, CSO Vaccine Immunotherapeutics, Pfizer Inc
Dr Howard Kaufman
Cancer & Immunotherapy

Updated clinical progress on Amgen's oncolytic virus-based immunotherapy T-VEC against melanoma

  • Progression and update on phIII clinical data
  • Demonstrating significantly higher durable tumor response rate 
  • T-Vec in combination with prime boost, mAB and check point inhibitors in more cancers 
Dr Howard Kaufman, Chief Surgical Officer, Assoc Director, Rutgers Cancer Institute of New Jersey
Mr Jagannadha Sastry
Cancer & Immunotherapy

Check point modulation in combination with vaccine and chemotherapy for curative treatment of HPV cancers

  • Using CAR T-cell therapy for optimal anti-cancer treatment
  • Future challenges for the CAR T-cell approach and combinations with other cancer treatments and vaccines
Mr Jagannadha Sastry, Professor of Immunology., The University of Texas MD Anderson Cancer Center
Dr Lelia Delamarre
Cancer & Immunotherapy

Neoantigens in cancer immunotherapy

  • Review of published data showing that mutations drive protective T cell response in cancer
  • Importance of neoantigen selection
  • Clinical applications
Dr Lelia Delamarre, Group Leader, Cancer Immunotherapy Department, Genetech

Networking coffee break

Dr Jessica Baker Flechtner
Cancer & Immunotherapy

Smarter identification of T cell antigens from infectious disease to cancer

  • T cells play a critical role in protection from both infectious disease and cancer
  • Antigen selection matters – immunodominance does not always equal protection
  • Broad protection requires pan-HLA insights and polyclonal T cell responses
  • ATLAS™ is a proven platform that can comprehensively and rapidly characterize the specificity and quality of HLA-diverse human T cell responses, without any guesswork 
  • Proven also in infectious disease, data will offer rare insights into natural T cell-mediated immunity to cancer
Dr Jessica Baker Flechtner, Chief Scientific Officer, Genocea Biosciences, Inc.
Dr Jay A. Berzofsky
Cancer & Immunotherapy

Combining immunotherapy with a novel chemotherapy in mouse tumor models

  • Chemotherapy-mediated induction of cancer immunogenic cell death to serve as an endogenous cancer vaccine.
  • Synergy of an endogenous cancer vaccine with checkpoint blockade.
  • Combinations of an endogenous cancer vaccine with immune enhancing immunostimulatory agents.
Dr Jay A. Berzofsky, Branch Chief, Vaccine Branch, National Cancer Institute - NIH

Networking Lunch

Dr Gregory A. Poland

Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
Dr Thomas Breuer

ABCs of Supply and Demand: Creating the Future

-    Appreciating the intricacies of the vaccine industry: Roles and structure of the Industry, R&D and manufacturing cycles    
-    Industry future: Health solutions and business challenges
-    How we achieve business sustainability and meet global vaccine needs
-    Measuring and recognizing the full economic and social value of vaccines
-    What the industry, partners and governments need to do
Dr Thomas Breuer, Senior Vice President, Chief Medical Officer, G.S.K. Vaccines
Dr Carol J. Baker

Do we need a new strategy for maternal immunization?

  • Are vaccines that benefit the baby more than the mother acceptable?
  • Have we progressed in our understanding of maternal and neonatal vaccine immunology?
  • Where are we with development of vaccines that affect maternal and infant health (e.g., group B Streptococcus, respiratory syncytial virus, pertussis and influenza)?
Dr Carol J. Baker, Head of Infectious Disease Professor of Pediatrics, Baylor College of Medicine
Dr Jerome Kim

A MERS vaccine: Doing research and vaccine development preemptively

  • For-profit vaccine companies will find it difficult to make vaccines that are not used except in an emergency
  • Governments can and do fund the production of vaccines that are not commercially viable but bear the risks of discovery and the burden of development
  • MERS is not the herald of an impending epidemic apocalypse but public health, and the vaccines necessary to maintain it, is not free or easy
Dr Jerome Kim, Director-General, International Vaccine Institute
Dr Gregory A. Poland

Chair’s closing remarks and close of congress

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
last published: 24/Mar/16 11:26